Individual Investors in Zhejiang Medicine Co., Ltd. (SHSE:600216) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 5.9% Last Week
Individual Investors in Zhejiang Medicine Co., Ltd. (SHSE:600216) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 5.9% Last Week
Key Insights
主要见解
- Significant control over Zhejiang Medicine by individual investors implies that the general public has more power to influence management and governance-related decisions
- The top 25 shareholders own 46% of the company
- Past performance of a company along with ownership data serve to give a strong idea about prospects for a business
- 个人投资者对浙江医药的重要控制权意味着普通公众对于管理和治理相关决策有更大的影响力。
- 前 25 名股东拥有该公司的 46%。
- 公司过去的业绩以及所有权数据,有助于形成对业务前景的强烈想法。
To get a sense of who is truly in control of Zhejiang Medicine Co., Ltd. (SHSE:600216), it is important to understand the ownership structure of the business. We can see that individual investors own the lion's share in the company with 53% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
要想真正了解浙江医药股份有限公司(上海证券交易所股票代码:600216)的控制权归属,了解商业公司的所有权结构是很重要的。我们可以看到个人投资者拥有该公司53%的所有权。这意味着,该群体在股票上涨时获得最大利益(在下跌时则损失最大)。
Clearly, individual investors benefitted the most after the company's market cap rose by CN¥546m last week.
显然,上周浙江医药的市值上涨了人民币54600万元,其中个人投资者获益最多。
Let's take a closer look to see what the different types of shareholders can tell us about Zhejiang Medicine.
让我们更近距离地观察一下不同类型的股东对于浙江医药有什么样的启示。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240622/0-bba1c93cd3f1578f36defa87628a7b0e-0-6ad6434f2575e84f80361a94f5632d32.png/big)
What Does The Institutional Ownership Tell Us About Zhejiang Medicine?
机构持股向我们传递了关于浙江医药的哪些信息?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
机构通常在向自己的投资者报告时会针对一个基准进行衡量,因此一旦某只股票被纳入主要指数,他们通常会更加热衷于该股票。我们预计大多数公司都会有一些机构在登记簿上,尤其是那些正在增长的公司。
Zhejiang Medicine already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Zhejiang Medicine's historic earnings and revenue below, but keep in mind there's always more to the story.
浙江医药股份有限公司的股权登记簿上已经有了机构的身影,机构持有该公司的股票,这表明投资界普遍认为该公司有一定的信誉。然而,完全依赖于机构型投资者所带来的所谓认可是比较危险的。他们也会犯错误。当多个机构持有某只股票时,存在他们会进行“拥挤交易”的风险,一旦这种交易失败,多方将快速举行抛售并争夺股票的风险就会更高。这种风险在一家没有成长历史的公司中更高。你可以在下方查看浙江医药的历史收益和营业收入,但要记住,故事总会有更多的版本。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240622/0-bba1c93cd3f1578f36defa87628a7b0e-1-8b092b379972b98e9094bf06ec1e5769.png/big)
Zhejiang Medicine is not owned by hedge funds. Xinchang Changxin Investment Development Ltd. is currently the largest shareholder, with 22% of shares outstanding. In comparison, the second and third largest shareholders hold about 16% and 1.8% of the stock.
浙江医药并没有被对冲基金持有,新昌长新投资发展有限公司目前是最大的股东,持有22%的股份。相比之下,第二和第三大股东分别持有该股的16%和1.8%。
A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.
对我们的所有权数据进行更深入的研究表明,前25名股东的持股总额不到注册表的一半,表明有一个小股东的大群体,其中没有单个股东拥有多数股份。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.
虽然研究公司的机构持股可以增加您的研究价值,但研究分析师的建议以加深对股票预期表现的全面了解也是一个好习惯。虽然有部分分析师的覆盖,但该公司可能没有受到广泛的关注。因此,在未来可能会受到更多关注。
Insider Ownership Of Zhejiang Medicine
浙江医药内部股权情况
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
内部人员的定义在不同国家可能略有不同,但董事会成员总是计入内部人员。管理层最终向董事会回答。然而,经理往往会成为执行董事会成员,尤其是如果他们是创始人或CEO。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
当内部人持股情况表明领导层思考和公司真正所有者一样时,内部所有权是积极的。然而,高达内部人士所有权也可能为公司内的小团体带来巨大的权力。在某些情况下,这可能是负面的。
Our most recent data indicates that insiders own less than 1% of Zhejiang Medicine Co., Ltd.. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. It is a pretty big company, so it would be possible for board members to own a meaningful interest in the company, without owning much of a proportional interest. In this case, they own around CN¥38m worth of shares (at current prices). It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.
我们最近的数据显示,内部人持有浙江医药股份有限公司的股份不到1%。但是,我们注意到内部人可能会通过私人公司或其他公司机构间接持有股权。它实际上是一家相当大的公司,董事会成员可以拥有公司较大的股权,但在这种情况下,他们持有最多价值人民币3800万元的股票(按照现价计算)。看到至少有一些内部人持股总是好的,但值得检查他们是否一直在出售。
General Public Ownership
一般大众所有权
The general public, who are usually individual investors, hold a substantial 53% stake in Zhejiang Medicine, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.
普通公众,通常是个人投资者,持有浙江医药的53%的股权,这意味着这是一只相当受欢迎的股票。这种持股数量赋予普通公众一定的集体权力,他们可以并且很可能会影响高层薪酬、红利政策以及拟议中的业务收购决策。
Private Equity Ownership
股权投资公司持有8.8%的股份,有能力参与塑造以价值创造为重点的公司策略。一些投资者可能会因此而受到鼓舞,因为股权投资公司有时可以鼓励市场看到公司的价值,从而采取有益的策略。另外,那些持有者可能在将其上市后退出投资。
Private equity firms hold a 16% stake in Zhejiang Medicine. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
股权投资公司持有浙江医药16%的股权,这表明他们在重要政策决策上能够发挥影响力。有些人可能会喜欢这一点,因为股权投资公司有时是持有管理公司负责人的激进派。但是,有时候私人股权公司也会退出并使公司上市。
Private Company Ownership
私有公司的所有权
It seems that Private Companies own 24%, of the Zhejiang Medicine stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
似乎私人公司持有浙江医药24%的股权。私人公司可能是相关方。有时候,内部人物通过持有私人公司的股权而不是以个人身份持有上市公司的股权。虽然很难得出任何广泛的结论,但值得注意的是,这是进一步研究的领域。
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand Zhejiang Medicine better, we need to consider many other factors. Be aware that Zhejiang Medicine is showing 2 warning signs in our investment analysis , you should know about...
思考不同群体持有股票的情况总是值得的。但是,要更好地了解浙江医药,我们需要考虑许多其他因素。请注意,我们的投资分析表明,浙江医药存在2个警示信号,应该了解。
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
但最终,决定该业务所有者将获得多大利益的是未来而非过去。因此,我们认为最好查看此免费报告,以了解分析师是否预测更光明的未来。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。